Aspray TJ, Hill TR (2019) Osteoporosis and the ageing skeleton. Subcell Biochem 91:453–476. https://doi.org/10.1007/978-981-13-3681-2_16

Article  CAS  PubMed  Google Scholar 

Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M et al (2021) Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res 33:759–773. https://doi.org/10.1007/s40520-021-01817-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287. https://doi.org/10.1016/S0140-6736(10)62349-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lunenfeld B, Stratton P (2013) The clinical consequences of an ageing world and preventive strategies. Best Pract Res Clin Obstet Gynaecol 27:643–659. https://doi.org/10.1016/j.bpobgyn.2013.02.005

Article  PubMed  PubMed Central  Google Scholar 

Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S et al (2021) Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:669. https://doi.org/10.1186/s13018-021-02821-8

Article  PubMed  PubMed Central  Google Scholar 

Lee YK, Yoon BH, Koo KH (2013) Epidemiology of osteoporosis and osteoporotic fractures in South Korea. Endocrinol Metab 28:90–93. https://doi.org/10.3803/EnM.2013.28.2.90

Article  Google Scholar 

Ahn SH, Park SM, Park SY, Yoo JI, Jung HS, Nho JH et al (2020) Osteoporosis and osteoporotic fracture fact sheet in Korea. J Bone Metab 27:281–290

Article  PubMed  PubMed Central  Google Scholar 

Reid IR (2020) A broader strategy for osteoporosis interventions. Nat Rev Endocrinol 16:333–339. https://doi.org/10.11005/jbm.2020.27.4.281

Article  PubMed  Google Scholar 

Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG et al (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176:224–238. https://doi.org/10.7326/M22-1034

Article  PubMed  PubMed Central  Google Scholar 

Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA (2015) Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes 6:598–612. https://doi.org/10.4239/wjd.v6.i4.598

Article  PubMed  PubMed Central  Google Scholar 

Oh SH, Ku H, Park KS (2021) Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data. BMC Public Health 21:548. https://doi.org/10.1186/s12889-021-10450-3

Article  PubMed  PubMed Central  Google Scholar 

Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM et al (2021) Diabetes fact sheet in Korea 2021. Diabetes Metab J 46:417–426. https://doi.org/10.4093/dmj.2022.0106

Article  Google Scholar 

Eller-Vainicher C, Cairoli E, Grassi G, Grassi F, Catalano A, Merlotti D et al (2020) Pathophysiology and management of type 2 diabetes mellitus bone fragility. J Diab Res. https://doi.org/10.1155/2020/7608964

Article  Google Scholar 

Cipriani C, Colangelo L, Santori R, Renella M, Mastrantonio M, Minisola S et al (2020) The interplay between bone and glucose metabolism. Front Endocrinol. https://doi.org/10.3389/fendo.2020.00122

Article  Google Scholar 

Mera P, Ferron M, Mosialou I (2018) Regulation of energy metabolism by bone-derived hormones. Cold Spring Harb Perspect Med 8:a031666. https://doi.org/10.1101/cshperspect.a031666

Article  CAS  PubMed  PubMed Central  Google Scholar 

Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S et al (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int 23(1):S1-23. https://doi.org/10.1007/s00198-011-1891-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lyu H, Zhao SS, Zhang L, Wei J, Li X, Li H et al (2023) Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. BMJ 381:e073435. https://doi.org/10.1136/bmj-2022-073435

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang HK, Chuang AT, Liao TC, Shao SC, Liu PP, Tu YK et al (2024) Denosumab and the risk of diabetes in patients treated for osteoporosis. JAMA Netw Open 7:e2354734. https://doi.org/10.1001/jamanetworkopen.2023.54734

Article  PubMed  PubMed Central  Google Scholar 

Henney AE, Riley DR, O’Connor B, Hydes TJ, Anson M, Zhao SS et al (2024) Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: n analysis of real-world, cohort data, with a systematic review and meta-analysis. Diabetes Obes Metab 26:3673–3683. https://doi.org/10.1111/dom.15708a

Article  CAS  PubMed  Google Scholar 

Rathmann W, Kostev K (2024) Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study. Osteoporos Int 35:2099–2106. https://doi.org/10.1007/s00198-024-07182-6

Article  CAS  PubMed  Google Scholar 

Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718–728. https://doi.org/10.3346/jkms.2017.32.5.718

Article  PubMed  PubMed Central  Google Scholar 

Xing B, Yu J, Zhang H, Li Y (2023) RANKL inhibition: a new target of treating diabetes mellitus? Ther Adv Endocrinol Metab 14:20420188231170750. https://doi.org/10.1177/20420188231170754

Article  PubMed  PubMed Central  Google Scholar 

Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S (2023) RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest 133:e169317. https://doi.org/10.1172/JCI169317

Article  PubMed  PubMed Central  Google Scholar 

Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183–190. https://doi.org/10.1038/nm1166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calle M, Fernandez M (2012) Inflammation and type 2 diabetes. Diabetes Metab 38:183–191. https://doi.org/10.1016/j.diabet.2011.11.006

Article  CAS  PubMed  Google Scholar 

Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer LC, Chines A et al (2020) Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone 134:115268. https://doi.org/10.1016/j.bone.2020.115268

Article  CAS  PubMed  Google Scholar 

Napoli N, Pannacciulli N, Vittinghoff E, Crittenden D, Yun J, Wang A et al (2018) Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab Res Rev 34:e2991. https://doi.org/10.1002/dmrr.2991

Article  CAS  PubMed  Google Scholar 

Pacheco-Soto BT, Elguezabal-Rodelo RG, Porchia LM, Torres-Rasgado E, Pérez-Fuentes R, Gonzalez-Mejia ME (2021) Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis. J Drug Assess 10:97–105. https://doi.org/10.1080/21556660.2021.1989194

Article  CAS  PubMed  PubMed Central